Losartan Potassium

氯沙坦钾

Report date: 2026/04/25 20:00:23
NME

Base Information

Drug NameLosartan Potassium
Drug Alias NameLosartankalium洛沙坦钾Kalii LosartanumLosartaanikaliumLosartan Potasyum +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)CognitionEmotional Regulation +[39] 
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1995/04/14
Country/TerritoryCanadaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesOrganonUtah State UniversitySteadman Philippon Research Institute +[8] 
Inactive CompaniesThe Interuniversity Cardiology Institute Of The NetherlandsOffice Of Rare DiseasesWake Forest University +[24] 
Active IndicationsCognitionEmotional RegulationKeloid +[12] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Tendon InjuriesDrug-Related Side Effects and Adverse Reactions +[27] 

Other Information

ATC CodeC09CA01
Related LinksWikipediaDrugBankKEGG